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fection is the development of pneumonia, caused either
directly by the influenza virus, or by secondary bacterial
infection. Pneumonia related to the 2009 influenza A pan-
demic was found to be underestimated by commonly used
pneumonia severity scores in many cases, and to be rapidly
progressive, leading to respiratory failure. Confirmation of
etiology by laboratory testing is warranted in such cases.
Rapid antigen and immunofluorescence testing are useful
screening tests, but have limited sensitivity. Confirmation of
pandemic H1N1 influenza A infection can only be made by
real-time reverse-transcriptase polymerase chain reaction
(rRT-PCR) or viral culture. The most effective preventive
measure is annual influenza vaccination in selected individu-
als. Decisions to administer antiviral medications for influenza
treatment or chemoprophylaxis should be based upon clinical
and epidemiological factors, and should not be delayed by
confirmatory laboratory testing results. Neuraminidase inhib-
itors (NI) are the agents of choice.
Prevention . Swine influenza . Avian influenza . H1N1 .
Pandemic
Introduction
Influenza is acute respiratory illness caused by influenza A
or B viruses with seasonal circulation during the winter
months. However, outbreaks of novel recombinant strains
that take place in animals have produced, along the years,
many worldwide outbreaks with serious public health
issues. Although normally a self-limited process in the gen-
eral population, high risk groups for complications and
death have been identified (Table 1). During an outbreak,
in otherwise healthy subjects the diagnosis of influenza
infection can be made confidently based on clinical mani-
festations alone. However, in certain situations, such as
sporadic cases, in patients at an increased risk for compli-
cations, or in hospitalized patients with severe pulmonary
compromise, confirmation of etiology by laboratory testing
is required to guide treatment and for surveillance purposes
[1••, 2••]. A potentially fatal complication of influenza in-
fection is the involvement of the lower respiratory tract
caused directly by the influenza virus, and the development
of secondary bacterial pneumonia. Novel recombinant in-
fluenza A strains carry the risk for more severe disease and
have the potential to cause widespread illness and a large
number of deaths, regardless of age or previous health status.
Examples of this are the H5N1 “avian” influenza A outbreak
since 2004, and the more recent H1N1 “swine” influenza A
pandemic in 2009, both of which have prompted the develop-
ment of quick and reliable laboratory test in an effort to opti-
mize their management and reduce morbidity and mortality. In
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this article, we review the latest available data for the diagnosis
of influenza lower respiratory tract infection, as well as for
treatment and prevention strategies.
Clinical and Radiological Diagnosis
Signs and symptoms of upper and/or lower respiratory tract
infection, along with systemic involvement in the form of
fever, myalgia, and headache, are usually the main present-
ing features of the disease. In the context of an outbreak,
otherwise healthy subjects presenting with a self-limited
acute febrile respiratory illness usually require no further
diagnostic procedures. In two retrospective studies that ex-
amined which clinical signs and symptoms are most predic-
tive of influenza infection in patients with influenza-like
illness, cough and fever were the only symptoms signifi-
cantly associated with a positive PCR test for influenza [3,
4]. In another study, no isolated symptom or sign was able to
accurately predict influenza infection, though the absence of
fever, cough and nasal congestion significantly decreased its
likelihood [5]. In general, patients diagnosed with pandemic
H1N1 influenza A virus had similar signs and symptoms
compared to those with seasonal influenza. However, these
patients had gastrointestinal manifestations more frequently
[6, 7], were more likely to have pneumonia [8], and also had
higher rates of extrapulmonary complications, intensive care
unit admission, and death [9].
Pneumonia is the most frequent and severe complication of
influenza, most commonly presenting in high risk patients
(Table 1). Primary influenza pneumonia represents direct lung
involvement by influenza virus, and should be suspected in
non-resolving influenza infections. Typically, primary influ-
enza pneumonia presents in chest x-rays with bilateral reticu-
lar or reticulonodular opacities. Less frequently, focal areas of
consolidation can be seen, particularly in the lower lobes.
High-resolution computed tomography may show ground
glass opacities with or without multifocal peribronchovascular
and subpleural consolidation [10].
The cytopathic effect of the influenza virus on the tracheo-
bronchial epithelium may predispose to secondary bacterial
pneumonia [11, 12]. Secondary bacterial pneumonia must be
suspected whenever there is an exacerbation of fever and
respiratory symptoms after initial improvement in a patient
diagnosed with acute influenza. Leukocytosis, instead of a
normal or low white blood cell count, and lobar consolidation
on chest imaging, instead of the diffuse pattern that is typical
of viral pneumonia, are also suggestive [13].
In an observational study of 543 hospitalized patients
with H1N1 influenza A infection in Spain, 43 % of the
243 patients in which chest radiographs were performed
had pneumonia, 83 % of the 210 patients who had microbi-
ologic confirmation had primary influenza pneumonia, and
the remaining 17 % had concomitant secondary bacterial
pneumonia. Bilateral pneumonia occurred in 48.3 % of
patients; Streptococcus pneumoniae being the most frequent
pathogen [14]. Several reports have identified methicillin-
resistant Staphylococcus aureus (MRSA) as the etiologic
agent for severe community acquired pneumonia (CAP) in
otherwise healthy young patients with influenza [15–17]. In
another study that investigated the incidence of community-
acquired MRSA pneumonia in H1N1 influenza patients, 50
patients of 4491 (1 %) laboratory-confirmed pandemic in-
fluenza A (H1N1) cases had a bacterial respiratory tract
pathogen. The most commonly cultured organisms were S.
pneumoniae (16 patients), S. aureus (13 patients) and Hae-
mophilus influenzae (9 patients); MRSA was detected in
only 2 patients [18]. In contrast, among 838 children and
adolescents admitted to 35 intensive care units in the U.S.
with confirmed or probable severe H1N1 influenza A infec-
tion, 48 % of the 71 patients with suspected diagnosis of
early S. aureus coinfection had MRSA [19].
Non-seasonal influenza infections have specific clinical man-
ifestations. Pneumonia related to the 2009 H1N1 influenza A
pandemic was also found in many cases to be rapidly progres-
sive, leading to respiratory failure and ARDS [20•, 21•]. Addi-
tionally, the risk for complications and death due to that
Table 1 Persons at higher risk for influenza complications
Children <2 years
Adults ≥65 years
Women who are pregnant or postpartum (within 2 weeks after
delivery)
Individuals with chronic medical conditions
Pulmonary disease (including asthma)





Hemoglobinopathies (including sickle cell disease)
Immunosuppression 1
Any neurologic condition that can compromise handling of
respiratory secretions 2
Native Americans and Alaska Natives
Morbidly obese persons (body-mass index ≥40)
Residents of nursing homes and other chronic-care facilities
(1) Including HIV infection (particularly if CD4 <200 cells/microL),
organ or hematopoietic cell transplantation and inflammatory disorders
treated with immunosuppressants
(2) Including disorders of the brain, spinal cord, peripheral nerve, and
muscle such as cerebral palsy, seizure disorders, stroke, intellectual
disability, moderate to severe developmental delay, muscular dystro-
phy, or spinal cord injury
Adapted from the recommendations of the Advisory Committee on
Immunization Practices (ACIP) [40••]
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pandemic influenza was found to be underestimated by com-
monly used pneumonia severity scores [22•, 23]. Avian influ-
enza (H5N1) frequently presents as severe primary pneumonia
that often progresses rapidly to the acute respiratory distress
syndrome (ARDS), having caused high rates of death, espe-
cially among infants and young children in Southeast Asian
countries [24].
Laboratory Testing
In certain situations, confirmation of etiology by laboratory
testing is required in order to guide the initiation and duration
of antiviral therapy, and for the implementation of infection
control measures and surveillance. Other benefits of influenza
virus detection are the reduction of inappropriate antibiotic
use, decreased length of stay in emergency departments, and
fewer additional laboratory studies, all leading to a reduction
in health care costs [1••]. The Centers for Disease Control and
Prevention (CDC) and the Infectious Diseases Society of
America (IDSA) have published guidelines to better define
patients who should undergo influenza testing [1••, 2••]. The
available methods include immunological techniques (i.e.
rapid antigen-based tests, immunofluorescence assays, sero-
logic testing), molecular techniques (i.e. reverse-transcriptase
polymerase chain reaction [RT-PCR]), and microbiological
techniques (i.e. viral cultures). While RT-PCR has the highest
sensitivity and specificity, rapid antigen and immunofluores-
cence testing, though very useful as initial screening tests, are
considerably less sensitive. Besides, the sensitivity and spec-
ificity of any of these techniques will vary depending on the
laboratory equipment, personnel expertise, the timing of rec-
ollection, and the appropriate handling of the samples [1••,
2••]. Respiratory specimens can be obtained bymany different
methods including throat swabs, nasal aspirates, and nasopha-
ryngeal swabs, aspirates and washing [2••]. In mechanically
ventilated subjects, more invasive maneuvers such as endo-
tracheal aspirates and bronchoscopic or non-bronchoscopic
bronchoalveolar lavage (BAL) may be required in order to
obtain adequate lower respiratory tract samples. While rapid
antigen tests, immunofluorescence and RT-PCR all can yield
results quick enough to guide point-of-care clinical decision-
making, serologic tests and viral cultures provide retrospective
diagnosis, availability only in reference laboratories, and use-
fulness when confirming screening test. For this reason, they
are normally reserved for epidemiological and research pur-
poses (Table 2).
Rapid Influenza Diagnostic Tests
Rapid influenza diagnostic test (RIDT) are designed to detect
influenza A and B nucleoproteic antigens in respiratory
specimens, with results expressed qualitatively as positive or
negative in no more than 15 min. Many different FDA-
approved tests are available; while some assays are capable of
distinguishing between influenza A or B viruses, none can
distinguish between pandemic and seasonal strains of influenza
A [1••, 2••]. Compared to reference methods (i.e. RT-PCR and
viral culture), they have low sensibility (10 % to 80 %) and
high specificity (95 % to 100 %), and there is also great
variability between the different commercially available kits
[25–27]. Sensitivity appears to be somewhat lower for influen-
za B than that seen for influenza A [26]. Also, the reported
sensitivity for rapid tests is higher for nasopharyngeal samples
than for throat swabs [27]. There are two main factors that
influence RIDT’s negative predictive value. First, negative
results obtained during periods of high viral activity in the
community are more likely to be false negatives; alternatively,
false positives, though much less frequent, are more likely
during periods of less viral circulation. Second, respiratory
samples collected within the first 48 to 72 h of symptom onset
positively influence RIDT’s sensitivity. For these reasons,
when rapid tests are negative, confirmation by means of RT-
PCR or viral culture should be considered [1••, 2••]. Compared
to RT-PCR, the sensitivity of RIDTs for detecting novel influ-
enza A (H1N1) was equal to or lower than the sensitivity to
detect seasonal influenza viruses [29–32], so RIDT results need
to be interpreted with caution when evaluating patients sus-
pected of having pandemic H1N1 influenza A.
Immunofluorescence
Direct (DFA) or indirect (IFA) immunofluorescence anti-
body staining techniques are capable of detecting influenza
A and B viruses, and distinguish the viruses from each other as
well as from other respiratory viruses [1••, 2••]. They have
levels of sensitivity and specificity that come close to those of
RT-PCR [28, 33], and results are often available in a few hours
[1••, 2••]. Although these tests have improved sensitivity over
RIDT, they are more technically complex and require exper-
tise in obtaining quality respiratory samples (Table 2).
Reverse-Transcriptase Polymerase Chain Reaction
This is the reference influenza detection method and has the
highest sensitivity and specificity [34, 35]. Several modali-
ties of RT-PCR have been designed: conventional gel-based
PCR (cRT-PCR), multiplex PCR (mRT-PCR), and real-time
RT-PCR (rRT-PCR). They can differentiate between influ-
enza types (A or B) and subtypes (including pandemic H1N1
influenza and avian H5N1 influenza), and results are available
in 2–6 h (although due to transportation of batched specimens
to reference centers for processing, it may take longer for
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results to be available). During the 2009 H1N1 influenza A
pandemic, it became clear that rapid case identification was
essential for timely management of patients and for adequate
public health actions to be taken. To answer to this threat, the
CDC optimized the previously developed rRT-PCR proce-
dures for detection of the A/H1N1 2009 pandemic influenza
virus [36•]. Yang et al. compared the performance of 12 rRT-
PCR primer-probe sets designed for detecting the hemagglu-
tinin (HA) or the neuraminidase (NA) gene of the pandemic
influenza A/H1N1 2009 virus, using the primer-probe set
developed at the CDC as reference. They found that although
all primer-probe sets had specificity levels as high as 98.4% to
100 %, some of the primer-probe sets had better specificity,
sensitivity, and amplification efficiency than others, and that a
combination of primer-probe sets targeted to the HA and NA
genes had higher detection sensitivity than those targeting HA
or NA individually [37]. In another study, Lam et al. showed
that although rRT-PCR assays can be 10-fold more sensitive
than cRT-PCR, newly developed cRT-PCR assays targeting
the HA gene are a reliable alternative for laboratories where a
rRT-PCR machine is not available [38]. Sensitivity and spec-
ificity of these assays also depend on the type of respiratory
sample employed. For example, in a Spanish study that
assessed the utility of rRT-PCR for the diagnosis of the novel
influenza A/H1N1 virus, the authors reported that the diag-
nostic yield of combined nose and throat swabs was higher
than that of nasopharyngeal aspirates [39].
Viral Cultures and Serologic Tests
Even the fastest viral cultures techniques can take days to
demonstrate influenza cytopathic effects. Since they are not
suitable for initial clinical management, their utility during an
influenza outbreak is to confirm some negative test results
from RIDT and immunofluorescence. Viral cultures also pro-
vide information about circulating influenza strains and its
subtypes; this information is required for next season vaccine
production, for surveillance of the emergence of new influen-
za A strains, and for the detection of antiviral resistance.
Similarly, serologic tests (i.e., hemagglutinin inhibition,
ELISA, complement-fixation) that demonstrate a four-fold
increase in serum antibody titers between acute and convales-
cence phases of the disease, are only useful for retrospective
diagnosis or research purposes (Table 2).
Treatment and Prevention
Annual immunization is the most important preventive mea-
sure [40••]. However, two classes of antiviral drugs are
available and play an important role in the treatment and
prevention of influenza [41••]: the neuraminidase inhibitors
(NI), oseltamivir and zanamivir, which are active against
both influenza A and B viruses; and the M2 inhibitors,
amantadine and rimantadine, which are active against all
influenza A strains, but have no activity against influenza B
viruses. In general, the duration for therapy with an NI is
5 days, and with the M2 inhibitors is three to 5 days.
Pharmacology
NI are sialic acid analogs that competitively inhibit neuramin-
idase on the surface of both influenza A and B, thus interfering
with the release of virus from infected cells. Oseltamivir phos-
phate is an orally bioavailable prodrug that is rapidly absorbed
from the gastrointestinal tract and is converted by hepatic
esterases to the active metabolite, oseltamivir carboxylate. It
has an elimination half-life of approximately 8 h, primarily
Table 2 Influenza testing methods
Method Test Time Specimen Sensitivity Specificity Distinguishes influenza
A from B
Influenza A subtypes
RITD 15 min. Respiratory samples 1 + +++ yes 2 no
Immuno-fluorescence 3 1-4 h. Respiratory samples 1 ++ +++ yes no
RT-PCR 4 1-6 h. Respiratory samples 1 +++ ++++ yes yes
Viral culture 5 1-10 d. Respiratory samples 1 ++ +++++
Serologic tests 2 w. Serum 6 n/a n/a yes yes
RIDT rapid influenza diagnostic tests, RT-PCR reverse-transcriptase polymerase chain reaction
(1) Appropriate respiratory samples vary for each method and should be obtained according to the manufacturer’s specifications
(2) Some commercially-available RIDT distinguish between influenza A and B while others do not
(3) Direct (DFA) or indirect (IFA) antibody staining
(4) Conventional gel-based PCR, real-time RT-PCR, and multiplex PCR
(5) Rapid viral cultures (shell vials) can yield results in 1-3 days, compared to conventional isolation in cell culture (3-10 days)
Adapted from the IDSA and CDC guidelines [1••, 2••]
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through the kidneys, and dose reduction is recommended for
patients with an estimated creatinine clearance of less than
30 mL/min. Approximately 15 % of inhaled zanamivir reaches
the bronchi and lungs. Excretion is primarily renal, but given
its limited systemic bioavailability, there is no need to modify
the dose in patients with renal insufficiency. The pulmonary
half-life is 2.8 h. Themost common toxicities reportedwithNI
have been nausea and vomiting (approximately 15 % of
patients). These side effects are usually mild and limited to
the first days of treatment, although more serious side effects
have been described. Oseltamivir has been linked to self-
injury and delirium in pediatric populations, although no
causal association could be demonstrated [42, 43]. The use
of inhaled zanamivir has been associated with bronchospasm,
sometimes severe or fatal, particularly in patients with under-
lying airways disease such as chronic obstructive pulmonary
disease (COPD) or asthma [44].
Amantadine and rimantadine target the M2 protein of
influenza A, which forms a proton channel in the viral
membrane that is essential for viral replication. Amantadine
is primarily excreted unchanged in the urine. In patients
older than 65 years and in those with an estimated creatinine
clearance of less than 50 mL/min, the daily dose should be
reduced. Rimantadine is extensively metabolized in the
liver, and dose reduction is recommended for patients with
severe hepatic dysfunction, renal failure (creatinine clear-
ance <10 mL/min), and the elderly. Central nervous system
(CNS) side effects are well described with amantadine,
particularly in elderly patients. In comparison, rimantadine
is associated with a considerably reduced rate of CNS side
effects [45].
Clinical Outcomes
In mild to moderate uncomplicated disease, the reported
benefits of early treatment (< 48 h of symptom onset) with
NI have been a shorter duration and severity of flu-like
symptoms, and a reduced duration of viral shedding
[46–49]. More importantly, several trials and a few system-
atic reviews have shown that treatment with NI may reduce
illness severity and the rate of lower respiratory tract com-
plications [47, 50–52]. In a meta-analysis of 10 randomized-
controlled trials, Kaiser et al. found that therapy with osel-
tamivir was effective in reducing the incidence of influenza-
related lower respiratory tract complications that required
antibiotic use (4.6 % for oseltamivir vs. 10.3 % for placebo,
P<0.001), independent of the presence of risk factors for
complications [51]. More recently, Hernán et al. conducted
another meta-analysis of 11 controlled trials, most of which
were included in the previous meta-analysis by Kaiser et al.
They found that treatment with oseltamivir significantly re-
duced influenza-related lower respiratory tract complications
by 37% (CI 95% [18–52]) [52]. NI have also been reported to
reduce the duration of hospitalization in severely-ill cases
[53], and also to reduce influenza-related mortality [54]. Dur-
ing the 2009 H1N1 Influenza A pandemic, several observa-
tional studies of hospitalized and critically-ill patients reported
that treatment with oseltamivir reduced disease severity, com-
plications and mortality [55–57]. In a Chinese study of 1291
patients with confirmed H1N1 influenza A infection, oselta-
mivir reduced the risk of developing pneumonia, even when
administered after the first 48 h of symptom onset (OR 0.12,
95 % CI [0.08–0.18]) [58]. In another retrospective study of
304 hematopoietic stem cell transplant recipients with influ-
enza infection, 161 patients had H1N1 influenza A confirmed
infection, and both early and delayed administration of anti-
viral therapy was shown to be beneficial in terms of decreased
risk of lower respiratory tract compromise (OR00.04, 95 %
CI [0–0.2] vs. OR00.14, 95 % CI [0–0.7]) [59]. An intrave-
nous form of zanamivir is under development, and was made
available during the 2009 H1N1 influenza A pandemic for
severely ill patients with highly suspected or confirmed
oseltamivir-resistant infection that could not tolerate inhaled
zanamivir. Several studies reported favorable outcomes with
the use of IV zanamivir [60–63].
During the 2009 swine influenza pandemic, the FDA briefly
authorized the emergency use of peramivir, an investigational
NI that is administered intravenously [64]. In one study, a
single dose of 300 mg or 600 mg of IV peramivir significantly
reduced the time to alleviation of symptoms compared with
placebo (HR 0.68 and 0.67 for the 300 mg and 600 mg doses
respectively) [65]. Laninamivir octanoate, another long acting
NI in development, was non-inferior to a five-day course of
oral oseltamivir in adults with seasonal influenza in one study
[66]. Experience with avian influenza H5N1, which has caused
sporadic cases since 2004 with an elevated mortality rate, is
much more limited and recommendations for its treatment are
in most cases extrapolated from trials of seasonal influenza.
There are, however, reports that suggest reduced severity and
mortality with the administration of oseltamivir in patients with
avian influenza [67–69]. In patients with pneumonia or with
clinical failure to standard regime with oseltamivir, a higher
dose of 150 mg bid for 10 days should be considered [24, 67].
In regions with adamantine-susceptible strains, combination
therapy with a NI and an adamantine may also be considered
with pneumonia or clinical worsening [24]. Therapy with osel-
tamivir should be administered even in the late course of
influenza A (H5N1) infection since viral replication is more
prolonged than with seasonal influenza [24].
Indications for Treatment
The United States Advisory Committee on Immunization
Practices (ACIP) and the CDC have recently published
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updated guidelines for the treatment of patients with con-
firmed or suspected influenza virus infections caused by
either pandemic H1N1 or seasonal strains [41••, 70••].
According to these recommendations, those individuals
with severe disease (requiring hospitalization or with evi-
dence of lower respiratory tract infection) or those at high
risk for complications (Table 1) should receive antiviral
therapy even after 48 h of symptom onset. Adults with mild
illness without high risk conditions who are younger than
65 years of age do not require treatment. If such individuals
present within the first 48 h of illness, antiviral treatment can
be considered in order to reduce the duration of illness. In all
cases, decisions to administer antiviral medications for
influenza treatment should be based on clinical and epide-
miologic grounds, and never be delayed because of confir-
matory laboratory tests [41••]. The usual dosing of
oseltamivir for the treatment of influenza is 75 mg orally
twice daily and of zanamivir is 10 mg (2 inhalations) twice
daily. The recommended duration for antiviral treatment is
5 days, although longer treatment courses for patients who
fail to improve after 5 days of treatment can be considered
[70••]. Also, doubling the dose of oseltamivir to 150 mg orally
twice daily has been suggested to be beneficial for some
severely ill patients with H5N1 avian influenza [24, 67]. The
FDA licensed oseltamivir for use in children 1 year of age and
older in a liquid formulation at a dosage of 2 mg/kg/dose twice
daily for 5 days. Zanamivir is not approved for use in children
under 5. Oseltamivir and zanamivir are Pregnancy Category C
drugs, but since influenza causes more severe disease and an
increased rate of mortality among pregnant women, they
should receive antiviral therapy with oseltamivir when indi-
cated, since the potential benefit outweighs the theoretical risk
to the fetus (Table 1).
Resistance
Although oseltamivir-resistant seasonal H1N1 influenza A
viruses have been identified since 2007 (the H274Ymutation)
[71], in 2009 the CDC reported that most circulating strains of
the novel H1N1 influenza A virus were sensitive to the NI,
oseltamivir and zanamivir, but that nearly all strains were
resistant to the amantadines [41••, 72]. Consequently, the
ACIP has advised against the use of M2 inhibitors for treat-
ment of influenza, except in selected circumstances [41••].
Additional Management Strategies
It is recommended that patients with pandemic H1N1 influenza
A who develop pneumonia be treated empirically for CAP
according to published evidence-based guidelines, given the
risk of secondary bacterial pneumonia [73]. In the presence of
profound hypoxemia that has been refractory to routine me-
chanical ventilation, salvage therapies include neuromuscular
blockade, inhaled nitric oxide, high-frequency oscillatory ven-
tilation, extracorporeal membrane oxygenation (ECMO), and
prone positioning ventilation [74•, 75]. Corticosteroids should
not be used routinely, but may be considered for septic shock
with suspected adrenal insufficiency requiring vasopressors
[76]. Therapy for influenza-associated ARDS should be based
upon published evidence-based guidelines for sepsis-associated
ARDS, specifically including lung protective mechanical venti-
lation strategies [76].
Prevention
The CDC recommends routine annual influenza vaccination
for all persons 6 months of age and older. When vaccine
supply is limited, vaccination efforts should focus on those
groups with health conditions associated with increased risk
of influenza complications [40••]. Antiviral drugs should
not be used as a substitute for influenza vaccination. Their
adjunctive use is appropriate in certain targeted populations
at high risk for complications of influenza who are close
contacts with suspected or confirmed cases [Table 1]. Post-
exposure prophylaxis should only be used when antivirals
can be started within 48 h of the most recent exposure.
Recommended duration is 7 days after exposure, and the
CDC recommends a minimum of 2 weeks for control of
influenza outbreaks in long–term care facilities (i.e., nursing
homes with elderly) and hospitals [70••]. The choice to offer
post-exposure prophylaxis to otherwise healthy unvaccinated
adults should be weighed against the risk of promoting anti-
viral drug resistance [41••, 1••].
Conclusions
A potentially fatal complication of influenza infection is the
involvement of the lower respiratory tract caused directly by
the influenza virus, and the development of secondary bac-
terial pneumonia. In these cases, and in patients who are at
an increased risk for influenza infection complications, con-
firmation of etiology by laboratory testing is required in
order to guide the initiation and duration of antiviral treat-
ment, and for the implementation of infection control meas-
ures and surveillance. Recently, the emergence of novel
influenza A strains that carry the risk for more severe
disease regardless of age or previous health status, has
prompted the development of quick and reliable laboratory
tests in an effort to optimize their management and reduce
morbidity and mortality. Pneumonia related to the 2009
influenza A pandemic was found in many cases to be
rapidly progressive, leading to respiratory failure which in
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many cases was underestimated by commonly used pneu-
monia severity scores. Given the limited sensitivity of RIDT
and immunofluorescence assays, confirmation of pandemic
H1N1 influenza A infection can only be made by rRT-PCR
or viral culture. Although annual immunization is the most
important preventive measure, NI are the agents of choice
for chemoprophylaxis in selected high risk patients, and for
treatment. Treatment with NI beyond 48 h of symptoms
should be considered only for patients with severe disease.
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